Primary source: Zus Health via GlobeNewswire, November 10, 2026, 9:37 a.m. ET
On November 10, 2026, Zus Health announced a $33 million Series B led by Drive Capital. If you run revenue cycle, the check is for a clinical data platform, and the use case in the release that touches payment is risk adjustment. The release does not mention claims, denials, or prior authorization.
Series B led by Drive Capital. Zus says total capital raised is now more than $100 million. No valuation, revenue, or customer name was disclosed.
The release is datelined Boston, November 10, 2026, and timed at 9:37 a.m. ET on GlobeNewswire. Sanofi Ventures, HealthX Ventures, and Alumni Ventures participated, along with existing investors Andreessen Horowitz (a16z), F-Prime, Maverick Ventures, and JAZZ Venture Partners. The money, Zus says, supports the intelligent patient record platform, the national healthcare data network, and AI-powered clinical workflows.
| Element | What the November 10 release says |
|---|---|
| Round | $33 million Series B. Total capital raised is now more than $100 million. |
| Who wrote checks | Drive Capital leads. Sanofi Ventures, HealthX Ventures, and Alumni Ventures participated. Existing investors: Andreessen Horowitz (a16z), F-Prime, Maverick Ventures, and JAZZ Venture Partners. |
| What the money is for | The intelligent patient record, the national data network, and AI clinical workflows. Zus also names three priorities: clinical intelligence, broader connectivity and fresher records, and more workflows in value-based care and specialty care. |
| Scale, as Zus reports it | In August alone, the network supported more than 110 million networked transactions. The AI-native clinical platform generated 39 million evidence citations year-to-date. |
| Trust marks | Candidacy to become a Qualified Health Information Network under TEFCA, announced in August 2026. HITRUST certified. |
| Valuation, revenue, named customers | Not disclosed. Customers are described as providers, value-based care organizations, payers, life sciences, and digital health companies. |
Goodwin’s same-day note repeats the round, the investor list, and the more-than-$100-million total, and says its healthcare and technology teams advised Zus. HIT Consultant restates the financing and the two activity counts. It also names CommonWell, Carequality, and HEDIS. Those three names are not in the GlobeNewswire release.
Zus was founded in 2021 by Jonathan Bush, co-founder and former CEO of athenahealth. Bush is founder and CEO. There is no earlier RevCycleAI article on this round.
The release describes three layers. The platform is the Zus Aggregated Profile, or ZAP: a unified longitudinal patient record with AI clinical intelligence. The network is nationwide connectivity across EHR networks, pharmacy data, care event notifications, labs, and other clinical sources, so the customer does not have to build that connectivity. The workflow layer is Zus-powered solutions and integration, so an organization can put the record to work or build its own application on it.
The use cases in the release are pre-visit preparation, transitions of care, risk adjustment, quality gap closure, and population health management. The clinical-intelligence product it names is AI-powered Generated Patient Summaries, which Zus calls GPS. The point of the paragraph, in the company’s words, is to move from retrieving records to building applications on a shared record.
“The story of electronic medical records doesn’t end with the silos we have today,” said Jonathan Bush, founder and CEO of Zus Health. “We’ve spent decades digitizing healthcare, but the information still doesn’t move with the patient. We’re building a networked medical record that changes that — connecting information across the healthcare system and making it available to the people and applications that need it. And now, with AI, we have an extraordinary opportunity to build workflows that actually make delivering care easier, faster, and more effective.”
“We believe healthcare is entering a new era in which AI can fundamentally change how care is delivered, but that transformation depends on having reliable, connected patient information,” said Molly Bonakdarpour, General Partner at Drive Capital. “Zus has built the foundation to address that challenge at scale. Its combination of technology, market opportunity, and leadership gives us conviction in the company’s ability to help shape the next generation of healthcare.”
Bush is talking about care delivery. Bonakdarpour is talking about care delivery. The payment problem sits one step downstream of the record they are describing, and the release leaves that step to the reader.
This release does not describe a claims system, a denial workflow, a prior-authorization product, or a dollar of recovered revenue. The 110 million networked transactions and the 39 million evidence citations are Zus’s counts. They are not a yield. No customer is named. No valuation is stated, and none is estimated here. “More than $100 million” is the company’s total. This article does not back into the earlier rounds. QHIN candidacy is a candidacy, announced in August 2026, not a designation.
This is RevCycleAI’s read. Risk adjustment is revenue. For a value-based organization, a condition the chart supports and nobody captured is a risk score that came in light. Zus puts risk adjustment in the same sentence as quality gap closure and population health. That is the use case in this release with a payment attached. The release does not say Zus calculates a RAF, drops a claim, or gets paid on the lift.
Your auth team and your appeal writers already do the assembly by hand. The note, the lab, and the pharmacy fill sit in systems the biller cannot open, and the clock runs while someone hunts them down. Zus says the network covers EHR networks, pharmacy data, care event notifications, labs, and other clinical sources, and that Generated Patient Summaries turn that pile into something a care team can use. If ZAP shortens the hunt, the round touches cost to collect. The release stops at the summary.
Two other stories landed the same day, on adjacent layers. Charta Health raised $55 million to run one chart-review engine for the clinic before the bill and for the plan after it. Google Cloud put Gemini for healthcare in preview, with read-only access to Epic and Oracle Health and connectors into the eligibility and prior-auth vendors already in the stack. Zus is trying to be the record under the chart those tools read. None of the three announced a connection to the others.
Zus just raised $33 million to move the record with the patient. The revenue-cycle use case in the release is risk adjustment. The 110 million transactions and 39 million citations are Zus’s counts. The valuation is blank, and the release does not mention a claim.
Ask whether ZAP is the chart, or a second chart beside the EHR. If you buy risk adjustment, that question changes the coder’s queue. The open items are a named customer, a price, and whether the August 2026 QHIN candidacy becomes a designation. Goodwin advised Zus. The counsel note confirms the round. It does not disclose terms.
Who wrote the check, which workflow actually touches payment, and the number the company printed.
Sources: Zus Health via GlobeNewswire, “Zus Health Raises $33 Million in Series B Funding to Accelerate the Next Generation of Connected Healthcare,” November 10, 2026, 9:37 a.m. ET, Boston (page opened); Goodwin, “Goodwin Advises Zus Health on Its $33 Million Series B Financing,” November 10, 2026 (page opened); HIT Consultant, Fred Pennic, November 10, 2026 (page opened); Business Insider markets page carrying the same release. Quotes from Jonathan Bush and Molly Bonakdarpour are verbatim from the GlobeNewswire release. The $33 million, the more-than-$100-million total, the investor names, the three layers, the August transaction count, the year-to-date citation count, the August 2026 QHIN candidacy, the HITRUST line, the use cases, and GPS are the release’s. CommonWell, Carequality, and HEDIS appear in the HIT Consultant article and do not appear in the GlobeNewswire release. No valuation, revenue, or customer name was disclosed, and none is estimated. There is no prior RevCycleAI Zus article.